NCT02483195.

Trial name or title	The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia
Methods	This is a double‐blind randomised active‐controlled trial
Participants	Inclusion criteria 50 female. Postmenopausal (> 60 years old or with total hysterectomy). Diagnosed with androgenetic alopecia. No chemical processing or changes in hair products throughout the study. Exclusion criteria Men. Premenopausal women (< 60 or without hysterectomy). Participants allergic to any of the study medications (minoxidil, finasteride, spironolactone). Participants with other co‐existing forms of alopecia (traction, alopecia areata, or scarring alopecias). Participants with obstructive uropathy or advanced liver disease. Prior hair loss treatment within the last 6 months. Hair loss from the chemotherapy or other medication‐induced alopecia. Hair loss for greater than 5 years, as medical therapy is unlikely to have much effect at restoring hair follicles inactive for that long of a period.
Interventions	Combination 5% minoxidil and 200 mg spironolactone. 5 mg finasteride with placebo topical preparation.
Outcomes	Primary outcomes The Savin Scale will be used to determine hair growth or hair loss between the groups, or both. The Ludwig Scale will be used to determine hair growth or hair loss between the groups, or both. Alopecia improvement assessment will be used to determine hair growth and/or hair loss between the groups (7‐point Likert scale).
Starting date	Not yet recruiting
Contact information	Andrea L Taylor, MD andrea.taylor@medicine.ufl.edu and Mark Correa mcorrea@ufl.edu
Notes	We accessed the website on 3 August 2015, which was last updated on 24 June 2015